INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5001, 16696, 'Entacapone', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5002, 24580, 'Entacapone', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5003, 0, 'Entrectinib', 'Grapefruit juice and Seville oranges may increase the plasma concentrations of entrectinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit and Seville oranges Inhibition of hepatic CYP450 3A4 may also contribute.', 'grapefruit juice', 'Major', 'Patients should avoid consumption of grapefruit, grapefruit juice, and Seville oranges during treatment with entrectinib.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5004, 2098, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5005, 2099, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5006, 6717, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5007, 7485, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5008, 18477, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5009, 18478, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5010, 18496, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5011, 18497, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5012, 28034, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5013, 28035, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5014, 33755, 'Eplerenone', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5015, 22120, 'Erlotinib', 'Grapefruit and grapefruit juice may increase the plasma concentrations of erlotinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Consumption of grapefruit and grapefruit juice should be avoided or limited during treatment with erlotinib.  Patients who currently smoke cigarettes are advised to stop smoking as soon as possible.  If cigarette smoking is continued while taking erlotinib, the manufacturer recommends increasing the dosage of erlotinib by 50 mg increments at 2-week intervals up to a maximum of 300 mg as tolerated.  However, the efficacy and long-term safety of dosages higher than 150 mg daily have not been established.  Data from a double-blind, randomized phase 3 study (MO22162, CURRENTS) demonstrated no benefit in progression free survival or overall survival with an erlotinib dosage of 300 mg daily relative to the recommended dosage of 150 mg daily in active smokers (average of 38 pack years) with locally advanced or metastatic NSCLC who have failed chemotherapy, although patients in the study were not selected based on epidermal growth factor receptor (EGFR) mutation status.  Safety data were comparable between the two dosages, but a numerical increase in the incidence of rash, interstitial lung disease and diarrhea was observed with the higher dosage.  Patients who have received a dosage increase should immediately revert to the recommended dosage of 150 mg or 100 mg once daily (depending on indication) upon cessation of smoking.  Erlotinib should be administered on an empty stomach at least one hour before or two hours after the ingestion of food.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5016, 27904, 'Erlotinib', 'Grapefruit and grapefruit juice may increase the plasma concentrations of erlotinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Consumption of grapefruit and grapefruit juice should be avoided or limited during treatment with erlotinib.  Patients who currently smoke cigarettes are advised to stop smoking as soon as possible.  If cigarette smoking is continued while taking erlotinib, the manufacturer recommends increasing the dosage of erlotinib by 50 mg increments at 2-week intervals up to a maximum of 300 mg as tolerated.  However, the efficacy and long-term safety of dosages higher than 150 mg daily have not been established.  Data from a double-blind, randomized phase 3 study (MO22162, CURRENTS) demonstrated no benefit in progression free survival or overall survival with an erlotinib dosage of 300 mg daily relative to the recommended dosage of 150 mg daily in active smokers (average of 38 pack years) with locally advanced or metastatic NSCLC who have failed chemotherapy, although patients in the study were not selected based on epidermal growth factor receptor (EGFR) mutation status.  Safety data were comparable between the two dosages, but a numerical increase in the incidence of rash, interstitial lung disease and diarrhea was observed with the higher dosage.  Patients who have received a dosage increase should immediately revert to the recommended dosage of 150 mg or 100 mg once daily (depending on indication) upon cessation of smoking.  Erlotinib should be administered on an empty stomach at least one hour before or two hours after the ingestion of food.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5017, 27905, 'Erlotinib', 'Grapefruit and grapefruit juice may increase the plasma concentrations of erlotinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Consumption of grapefruit and grapefruit juice should be avoided or limited during treatment with erlotinib.  Patients who currently smoke cigarettes are advised to stop smoking as soon as possible.  If cigarette smoking is continued while taking erlotinib, the manufacturer recommends increasing the dosage of erlotinib by 50 mg increments at 2-week intervals up to a maximum of 300 mg as tolerated.  However, the efficacy and long-term safety of dosages higher than 150 mg daily have not been established.  Data from a double-blind, randomized phase 3 study (MO22162, CURRENTS) demonstrated no benefit in progression free survival or overall survival with an erlotinib dosage of 300 mg daily relative to the recommended dosage of 150 mg daily in active smokers (average of 38 pack years) with locally advanced or metastatic NSCLC who have failed chemotherapy, although patients in the study were not selected based on epidermal growth factor receptor (EGFR) mutation status.  Safety data were comparable between the two dosages, but a numerical increase in the incidence of rash, interstitial lung disease and diarrhea was observed with the higher dosage.  Patients who have received a dosage increase should immediately revert to the recommended dosage of 150 mg or 100 mg once daily (depending on indication) upon cessation of smoking.  Erlotinib should be administered on an empty stomach at least one hour before or two hours after the ingestion of food.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5018, 524, 'Ergotamine', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Because grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4, the magnitude of interaction is greatest for those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability).  In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands.  Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5019, 16834, 'Eprosartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5020, 28036, 'Eprosartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5021, 28037, 'Eprosartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5022, 28092, 'Eprosartan', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5023, 16834, 'Eprosartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5024, 28036, 'Eprosartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5025, 28037, 'Eprosartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5026, 28092, 'Eprosartan', 'Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs).  ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion.  Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.', 'Food High in Potassium', 'Moderate', 'Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician.  If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended.  Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5027, 0, 'Ertugliflozin', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5028, 18454, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5029, 18455, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5030, 18457, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5031, 18458, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5032, 18459, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5033, 18471, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5034, 18472, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5035, 18836, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5036, 26062, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5037, 26063, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5038, 26064, 'Epirubicin', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury.  Epirubicin undergoes elimination through the hepatobiliary system.', 'alcohol', 'Moderate', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5039, 1078, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5040, 1773, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5041, 1786, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5042, 2610, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5043, 2617, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5044, 2618, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5045, 2672, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5046, 2674, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5047, 2677, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5048, 4387, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5049, 4388, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5050, 4416, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5051, 6737, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5052, 8940, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5053, 16358, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5054, 16421, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5055, 17021, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5056, 17416, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5057, 18542, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5058, 18544, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5059, 18546, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5060, 18584, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5061, 18585, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5062, 18687, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5063, 18688, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5064, 18689, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5065, 18690, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5066, 19512, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5067, 19513, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5068, 20412, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5069, 20413, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5070, 20414, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5071, 25472, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5072, 25473, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5073, 25690, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5074, 29143, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5075, 29787, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5076, 30442, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5077, 30456, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5078, 30495, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5079, 33743, 'Escitalopram', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5080, 86, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5081, 87, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5082, 240, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5083, 241, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5084, 4362, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5085, 4368, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5086, 4369, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5087, 4372, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5088, 18528, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5089, 18532, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5090, 18533, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5091, 18534, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5092, 18608, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5093, 18609, 'Erythromycin', 'Ethanol, when combined with erythromycin, may delay absorption and therefore the clinical effects of the antibiotic.  The mechanism appears to be due to slowed gastric emptying by ethanol.', 'alcohol', 'Minor', 'Patients  should be advised to avoid ethanol while taking erythromycin salts.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5094, 86, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5095, 87, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5096, 240, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5097, 241, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5098, 4362, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5099, 4368, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5100, 4369, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5101, 4372, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5102, 18528, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5103, 18532, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5104, 18533, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5105, 18534, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5106, 18608, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5107, 18609, 'Erythromycin', 'Food may variably affect the bioavailability of different oral formulations and salt forms of erythromycin.  The individual product package labeling should be consulted regarding the appropriate time of administration in relation to food ingestion.  Grapefruit juice may increase the plasma concentrations of orally administered erythromycin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Moderate', 'In general, optimal serum levels are achieved when erythromycin is taken in the fasting state, one-half to two hours before meals.  However, some erythromycin products may be taken without regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5108, 32029, 'Esketamine', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5109, 32029, 'Esketamine', 'Nausea and vomiting may occur following intranasal administration of esketamine.  In clinical studies, nausea and vomiting were reported in approximately 25% and 10% of esketamine-treated patients, respectively.', 'food', 'Moderate', 'To help prevent nausea and vomiting, patients should be advised not to eat for at least 2 hours before intranasal administration of esketamine and not to drink liquids for at least 30 minutes prior to administration.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5110, 1561, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5111, 1663, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5112, 3131, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5113, 3455, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5114, 3711, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5115, 4166, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5116, 4395, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5117, 4399, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5118, 4400, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5119, 4403, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5120, 4404, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5121, 4408, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5122, 4527, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5123, 4607, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5124, 4608, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5125, 4675, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5126, 5551, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5127, 5556, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5128, 5719, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5129, 5764, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5130, 6973, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5131, 7315, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5132, 8808, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5133, 8809, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5134, 8810, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5135, 8812, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5136, 9472, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5137, 9557, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5138, 10325, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5139, 11656, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5140, 13590, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5141, 13591, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5142, 14536, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5143, 14537, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5144, 15693, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5145, 18290, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5146, 18552, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5147, 18553, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5148, 18555, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5149, 18556, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5150, 18557, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5151, 18558, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5152, 18560, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5153, 18562, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5154, 18563, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5155, 18564, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5156, 18567, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5157, 18568, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5158, 18569, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5159, 18570, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5160, 18571, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5161, 18572, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5162, 18573, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5163, 18574, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5164, 18763, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5165, 22026, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5166, 22480, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5167, 22481, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5168, 22590, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5169, 22591, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5170, 23540, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5171, 23541, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5172, 23543, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5173, 23544, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5174, 23545, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5175, 23547, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5176, 23549, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5177, 23550, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5178, 23552, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5179, 23644, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5180, 24260, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5181, 24261, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5182, 24329, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5183, 25431, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5184, 25432, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5185, 27531, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5186, 27532, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5187, 28258, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5188, 29282, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5189, 30014, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5190, 30192, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5191, 30193, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5192, 30509, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5193, 30571, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5194, 31061, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5195, 31062, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5196, 32814, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5197, 32893, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5198, 33274, 'Esomeprazole', 'Food may interfere with the absorption of esomeprazole.  The manufacturer reports that the area under the concentration-time curve for esomeprazole following a single 40 mg dose was 33% to 53% lower when administered after food intake as opposed to during fasting conditions.', 'food', 'Moderate', 'Esomeprazole should be taken at least one hour before meals.  When administered to patients receiving continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for at least 1 hour before and 1 hour after the dose of esomeprazole is given.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5199, 0, 'Estazolam', 'Acute ethanol ingestion may potentiate the CNS effects of many benzodiazepines.  Tolerance may develop with chronic ethanol use.  The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during benzodiazepine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5200, 18549, 'Eslicarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5201, 18550, 'Eslicarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5202, 18551, 'Eslicarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5203, 21705, 'Eslicarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5204, 21706, 'Eslicarbazepine', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5205, 15472, 'Esmolol', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5206, 0, 'Esterified estrogens', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'food', 'Minor', 'It is not recommended to eat or drink foods containing grapefruit while taking any estrogen-based medications.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5207, 4418, 'Estramustine', 'Food and milk may significantly decrease serum concentrations of estramustine.  The mechanism of the interaction is not known.', 'dairy products', 'Moderate', 'It is recommended that estramustine be taken at least 1 hour before or 2 hours after meals, and that it not be coadministered with milk, or calcium containing products.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5208, 4438, 'Estradiol', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.  In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%.  Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol.  However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability.  Also, the effect on other estrogens has not been studied.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5209, 5083, 'Estradiol', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.  In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%.  Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol.  However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability.  Also, the effect on other estrogens has not been studied.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5210, 8063, 'Estradiol', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.  In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%.  Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol.  However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability.  Also, the effect on other estrogens has not been studied.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5211, 18914, 'Estradiol', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.  In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%.  Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol.  However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability.  Also, the effect on other estrogens has not been studied.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5212, 18915, 'Estradiol', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.  In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%.  Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol.  However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability.  Also, the effect on other estrogens has not been studied.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5213, 18916, 'Estradiol', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'grapefruit juice', 'Minor', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.  In a small, randomized, crossover study, the administration of ethinyl estradiol with grapefruit juice (compared to herbal tea) increased peak plasma drug concentration (Cmax) by 37% and area under the concentration-time curve (AUC) by 28%.  Based on these findings, grapefruit juice is unlikely to affect the overall safety profile of ethinyl estradiol.  However, as with other drug interactions involving grapefruit juice, the pharmacokinetic alterations are subject to a high degree of interpatient variability.  Also, the effect on other estrogens has not been studied.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5214, 1075, 'Amiloride', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5215, 20503, 'Amiloride', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5216, 5485, 'Estrone sulfate', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'food', 'Minor', 'It is not recommended to eat or drink foods containing grapefruit while taking any estrogen-based medications.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5217, 13001, 'Estrone sulfate', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'food', 'Minor', 'It is not recommended to eat or drink foods containing grapefruit while taking any estrogen-based medications.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5218, 13002, 'Estrone sulfate', 'Coadministration with grapefruit juice may increase the bioavailability of oral estrogens.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits.', 'food', 'Minor', 'It is not recommended to eat or drink foods containing grapefruit while taking any estrogen-based medications.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5219, 4829, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5220, 4832, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5221, 4833, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5222, 5268, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5223, 8937, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5224, 10561, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5225, 10562, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5226, 22202, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5227, 23437, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5228, 23589, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5229, 23590, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5230, 27085, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5231, 27088, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5232, 31620, 'Eszopiclone', 'Alcohol may potentiate some of the pharmacologic effects of zopiclone and eszopiclone.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving zopiclone or eszopiclone should be advised to avoid consumption of alcohol.  For faster sleep onset, eszopiclone and zopiclone should not be administered with or immediately after a high-fat/heavy meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5233, 24890, 'Etacrynic acid', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5234, 0, 'Ethionamide', 'The concomitant use of protionamide with alcohol may enhance the central nervous system exciting effect of protionamide.  The mechanism is not known.  Excessive use of alcohol with another thiocarbamide derivative ethionamide, has been reported to precipitate a psychotic reaction.  In addition, alcohol tolerance is reported to be reduced during protionamide treatment.', 'alcohol', 'Major', 'Consumption of alcohol during protionamide treatment should be avoided.  The manufacturer of ethionamide also advises that excess alcohol consumption should be avoided during ethionamide therapy (US).', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5235, 0, 'Ethchlorvynol', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5236, 4440, 'Ethosuximide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5237, 18605, 'Ethosuximide', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5238, 29189, 'Abemaciclib', 'Grapefruit juice may increase the plasma concentrations of abemaciclib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.  The interaction has not been studied with grapefruit juice, but has been reported for other CYP450 3A4 inhibitors.', 'grapefruit juice', 'Moderate', 'Abemaciclib may be administered with or without food.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with abemaciclib.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5239, 29190, 'Abemaciclib', 'Grapefruit juice may increase the plasma concentrations of abemaciclib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.  The interaction has not been studied with grapefruit juice, but has been reported for other CYP450 3A4 inhibitors.', 'grapefruit juice', 'Moderate', 'Abemaciclib may be administered with or without food.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with abemaciclib.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5240, 29191, 'Abemaciclib', 'Grapefruit juice may increase the plasma concentrations of abemaciclib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.  The interaction has not been studied with grapefruit juice, but has been reported for other CYP450 3A4 inhibitors.', 'grapefruit juice', 'Moderate', 'Abemaciclib may be administered with or without food.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with abemaciclib.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5241, 29192, 'Abemaciclib', 'Grapefruit juice may increase the plasma concentrations of abemaciclib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.  The interaction has not been studied with grapefruit juice, but has been reported for other CYP450 3A4 inhibitors.', 'grapefruit juice', 'Moderate', 'Abemaciclib may be administered with or without food.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with abemaciclib.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5242, 0, 'Etravirine', 'Coadministration with food increases the oral bioavailability of etravirine.', 'food', 'Moderate', 'Etravirine should always be administered following a meal.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5243, 24890, 'Etidronic acid', 'Food, especially calcium-containing food such as dairy products, significantly decreases the bioavailability of oral etidronate.', 'dairy products', 'Moderate', 'Oral etidronate should be administered on an empty stomach and no other food or drink should be taken within least 2 hours of administration.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5244, 4446, 'Etodolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5245, 4447, 'Etodolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5246, 4448, 'Etodolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5247, 4449, 'Etodolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5248, 22198, 'Etodolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5249, 23254, 'Etodolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5250, 25491, 'Etodolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5251, 25492, 'Etodolac', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5252, 0, 'Etomidate', 'Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5253, 2361, 'Everolimus', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus.  The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5254, 2419, 'Everolimus', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus.  The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5255, 2420, 'Everolimus', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus.  The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5256, 13565, 'Everolimus', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus.  The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5257, 13566, 'Everolimus', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus.  The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5258, 16172, 'Everolimus', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus.  The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5259, 16174, 'Everolimus', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered everolimus.  The mechanism is inhibition of CYP450 3A4 and P-glycoprotein activity in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients treated with everolimus should avoid consumption of grapefruit and grapefruit juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5260, 15591, 'Exenatide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5261, 15592, 'Exenatide', 'Alcohol may cause hypoglycemia or hyperglycemia in patients with diabetes.  Hypoglycemia most frequently occurs during acute consumption of alcohol.  Even modest amounts can lower blood sugar significantly, especially when the alcohol is ingested on an empty stomach or following exercise.  The mechanism involves inhibition of both gluconeogenesis as well as the counter-regulatory response to hypoglycemia.', 'alcohol', 'Moderate', 'Patients with diabetes should avoid consuming alcohol if their blood glucose is not well controlled, or if they have hypertriglyceridemia, neuropathy, or pancreatitis.  Patients with well controlled diabetes should limit their alcohol intake to one drink daily for women and two drinks daily for men (1 drink = 5 oz wine, 12 oz beer, or 1.5 oz distilled spirits) in conjunction with their normal meal plan.  Alcohol should not be consumed on an empty stomach or following exercise.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5262, 15591, 'Exenatide', 'Exenatide slows gastric emptying and may reduce the extent and rate of absorption of concomitantly administered oral medications.', 'food', 'Moderate', 'Concomitantly administered oral medications that are dependent on threshold concentrations for efficacy (e.g., antibiotics, contraceptives) or that require rapid gastrointestinal absorption (e.g., hypnotics, pain medications) should be administered at least 1 hour before exenatide.  If such medications are to be administered with food, patients should be advised to take them with a meal or snack when exenatide is not administered.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5263, 15592, 'Exenatide', 'Exenatide slows gastric emptying and may reduce the extent and rate of absorption of concomitantly administered oral medications.', 'food', 'Moderate', 'Concomitantly administered oral medications that are dependent on threshold concentrations for efficacy (e.g., antibiotics, contraceptives) or that require rapid gastrointestinal absorption (e.g., hypnotics, pain medications) should be administered at least 1 hour before exenatide.  If such medications are to be administered with food, patients should be advised to take them with a meal or snack when exenatide is not administered.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5264, 20757, 'Etonogestrel', 'Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of drugs that undergo significant presystemic metabolism by CYP450 3A4.  Grapefruit and grapefruit juice should be avoided if an interaction is suspected.  Orange juice is not expected to interact with these drugs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5265, 0, 'Ethotoin', 'Phenytoin bioavailability may decrease to subtherapeutic levels when the suspension is given concomitantly with enteral feedings.  The mechanism may be related to phenytoin binding to substances in the enteral formula (e.g., calcium, protein) and/or binding to the tube lumen.', 'dairy products', 'Moderate', 'Some experts have recommended interrupting the feeding for 2 hours before and after the phenytoin dose, giving the phenytoin suspension diluted in water, and flushing the tube with water after administration; however, this method may not entirely avoid the interaction and is not always clinically feasible.  Patients should be closely monitored for clinical and laboratory evidence of altered phenytoin efficacy and levels upon initiation and discontinuation of enteral feedings.  Dosage adjustments or intravenous administration may be required until therapeutic serum levels are obtained.  In addition, patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5266, 0, 'Fenfluramine', 'Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants.', 'alcohol', 'Moderate', 'Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease.  Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5267, 0, 'Ezogabine', 'Alcohol may increase the plasma concentrations of ezogabine.', 'alcohol', 'Moderate', 'In general, alcohol consumption should be avoided or limited during treatment with CNS-depressant agents.  Patients should be advised of the potential for increased dose-related adverse reactions of ezogabine (e.g., dizziness, somnolence, nausea, constipation, urinary retention, blurred vision, memory impairment, tremor) when taken with alcohol, and to avoid hazardous activities that require mental alertness and motor coordination until they know how the medication affects them.  Ezogabine can be taken with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5268, 0, 'Fedratinib', 'Grapefruit juice may increase the plasma concentrations of fedratinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.', 'grapefruit juice', 'Moderate', 'Fedratinib may be taken with or without food.  However, administration with a high-fat meal may help reduce the incidence of nausea and vomiting.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with fedratinib.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5269, 0, 'Fedratinib', 'Grapefruit juice may increase the plasma concentrations of fedratinib.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.  Inhibition of hepatic CYP450 3A4 may also contribute.', 'high-fat foods', 'Moderate', 'Fedratinib may be taken with or without food.  However, administration with a high-fat meal may help reduce the incidence of nausea and vomiting.  Patients should avoid consumption of grapefruit and grapefruit juice during treatment with fedratinib.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5270, 18905, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5271, 18906, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5272, 18907, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5273, 18908, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5274, 18909, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5275, 18910, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5276, 20281, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5277, 25003, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5278, 25004, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5279, 25005, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5280, 25006, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5281, 25007, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5282, 25008, 'Felodipine', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5283, 18905, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5284, 18906, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5285, 18907, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5286, 18908, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5287, 18909, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5288, 18910, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5289, 20281, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5290, 25003, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5291, 25004, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5292, 25005, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5293, 25006, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5294, 25007, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5295, 25008, 'Felodipine', 'The consumption of grapefruit juice may be associated with significantly increased plasma concentrations of some calcium channel blockers (CCBs) when they are administered orally.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Moderate', 'The manufacturers of nifedipine and nisoldipine recommend avoiding grapefruit juice.  Patients treated orally with other calcium channel blockers should be advised to avoid consumption of large amounts of grapefruits and grapefruit juice to prevent any undue fluctuations in serum drug levels.  Increased effects on blood pressure may persist for up to 4 days after the consumption of grapefruit juice.  Monitoring for calcium channel blocker adverse effects (e.g., headache, hypotension, syncope, tachycardia, edema) is recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5296, 0, 'Felbamate', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5297, 0, 'Fenoldopam', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'alcohol', 'Moderate', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5298, 4802, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5299, 13291, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5300, 13292, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5301, 17981, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5302, 17982, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5303, 17983, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5304, 17984, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5305, 17985, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5306, 18952, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5307, 18953, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5308, 18955, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5309, 30532, 'Fentanyl', 'Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including fentanyl.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.  In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.', 'alcohol', 'Major', 'Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with fentanyl.  Any history of alcohol or illicit drug use should be considered when prescribing fentanyl, and therapy initiated at a lower dosage if necessary.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with fentanyl should preferably avoid the consumption of grapefruit and grapefruit juice.  In addition, patients receiving transdermal formulations of fentanyl should be cautioned that drug interactions and drug effects may be observed for a prolonged period beyond removal of the patch, as significant amounts of fentanyl are absorbed from the skin for 17 hours or more after the patch is removed.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5310, 8544, 'Fenoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5311, 8545, 'Fenoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5312, 18948, 'Fenoprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5313, 4838, 'Ferrous sulfate anhydrous', 'Concomitant use of some food may reduce the bioavailability of orally administered iron, and vice versa.', 'food', 'Moderate', 'Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect.  Some studies suggest administration of iron with ascorbic acid may enhance bioavailability.  In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased.  Consult the product labeling for specific separation times and monitor clinical responses as appropriate.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5314, 4838, 'Ferrous fumarate', 'Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.', 'food', 'Moderate', 'Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect.  Some studies suggest administration of iron with ascorbic acid may enhance bioavailability.  In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased.  Consult the product labeling for specific separation times and monitor clinical responses as appropriate.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5315, 4838, 'Ferrous fumarate', 'Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.', 'orange juice', 'Moderate', 'Some studies have shown that taking iron with foods that are high in vitamin C (e.g., orange juice, etc.) improves bioavailability.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5316, 19888, 'Ferrous gluconate', 'Concomitant use of some food may reduce the bioavailability of orally administered iron, and vice versa.', 'food', 'Moderate', 'Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect.  Some studies suggest administration of iron with ascorbic acid may enhance bioavailability.  In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased.  Consult the product labeling for specific separation times and monitor clinical responses as appropriate.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5317, 14760, 'Fesoterodine', 'Coadministration with moderate inhibitors of CYP450 3A4 such as grapefruit juice may increase the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.  The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered.  Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.', 'grapefruit juice', 'Moderate', 'Caution is advised if fesoterodine is administered with grapefruit or grapefruit juice.  Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5318, 14761, 'Fesoterodine', 'Coadministration with moderate inhibitors of CYP450 3A4 such as grapefruit juice may increase the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.  The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered.  Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.', 'grapefruit juice', 'Moderate', 'Caution is advised if fesoterodine is administered with grapefruit or grapefruit juice.  Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5319, 20038, 'Fesoterodine', 'Coadministration with moderate inhibitors of CYP450 3A4 such as grapefruit juice may increase the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.  The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered.  Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.', 'grapefruit juice', 'Moderate', 'Caution is advised if fesoterodine is administered with grapefruit or grapefruit juice.  Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5320, 20039, 'Fesoterodine', 'Coadministration with moderate inhibitors of CYP450 3A4 such as grapefruit juice may increase the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme.  The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered.  Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.', 'grapefruit juice', 'Moderate', 'Caution is advised if fesoterodine is administered with grapefruit or grapefruit juice.  Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5321, 5457, 'Flavoxate', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5322, 23407, 'Flavoxate', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5323, 291, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5324, 292, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5325, 293, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5326, 383, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5327, 384, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5328, 385, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5329, 4719, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5330, 4720, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5331, 4721, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5332, 4853, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5333, 4854, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5334, 4857, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5335, 6172, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5336, 7761, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5337, 7762, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5338, 11246, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5339, 11247, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5340, 11248, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5341, 11589, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5342, 13777, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5343, 13778, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5344, 13792, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5345, 18855, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5346, 18856, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5347, 18862, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5348, 18863, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5349, 18864, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5350, 19024, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5351, 19025, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5352, 19027, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5353, 19029, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5354, 19030, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5355, 21853, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5356, 24263, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5357, 24264, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5358, 25712, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5359, 25713, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5360, 26547, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5361, 26548, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5362, 32786, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'grapefruit juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5363, 291, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5364, 292, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5365, 293, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5366, 383, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5367, 384, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5368, 385, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5369, 4719, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5370, 4720, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5371, 4721, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5372, 4853, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5373, 4854, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5374, 4857, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5375, 6172, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5376, 7761, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5377, 7762, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5378, 11246, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5379, 11247, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5380, 11248, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5381, 11589, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5382, 13777, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5383, 13778, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5384, 13792, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5385, 18855, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5386, 18856, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5387, 18862, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5388, 18863, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5389, 18864, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5390, 19024, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5391, 19025, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5392, 19027, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5393, 19029, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5394, 19030, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5395, 21853, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5396, 24263, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5397, 24264, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5398, 25712, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5399, 25713, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5400, 26547, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5401, 26548, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5402, 32786, 'Fexofenadine', 'Coadministration with large amounts of certain fruit juices, including grapefruit, orange and apple, may decrease the oral bioavailability of fexofenadine.  The proposed mechanism is inhibition of drug efflux via intestinal organic anion transporting polypeptides (e.g., P-glycoprotein), of which fexofenadine is a substrate.', 'orange juice', 'Moderate', 'To maximize plasma levels and therapeutic effects, fexofenadine should be taken with water.  In addition, patients should refrain from consuming large amounts of grapefruit, orange, or apple juice.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5403, 6486, 'Flibanserin', 'Grapefruit juice may increase the plasma concentrations of flibanserin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors such as grapefruit juice is considered contraindicated.  The patient should be advised to avoid the consumption of grapefruit and grapefruit juice during treatment, and to take flibanserin at bedtime to minimize the risk of hypotension, syncope, accidental injury, and central nervous system depression.  In addition, patients should consume no more than 1 to 2 alcoholic drinks and discontinue drinking alcohol at least two hours before taking flibanserin at bedtime; otherwise, they should skip the flibanserin dose that evening.  Alcohol should not be consumed until at least the morning after taking flibanserin at bedtime.  A standard alcoholic drink contains 14 g of pure alcohol and is equivalent to one 12-ounce regular beer (5% alcohol), 5-ounces wine (12% alcohol), or 1.5 ounces of distilled spirits/shot (40% alcohol).', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5404, 14290, 'Flibanserin', 'Grapefruit juice may increase the plasma concentrations of flibanserin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors such as grapefruit juice is considered contraindicated.  The patient should be advised to avoid the consumption of grapefruit and grapefruit juice during treatment, and to take flibanserin at bedtime to minimize the risk of hypotension, syncope, accidental injury, and central nervous system depression.  In addition, patients should consume no more than 1 to 2 alcoholic drinks and discontinue drinking alcohol at least two hours before taking flibanserin at bedtime; otherwise, they should skip the flibanserin dose that evening.  Alcohol should not be consumed until at least the morning after taking flibanserin at bedtime.  A standard alcoholic drink contains 14 g of pure alcohol and is equivalent to one 12-ounce regular beer (5% alcohol), 5-ounces wine (12% alcohol), or 1.5 ounces of distilled spirits/shot (40% alcohol).', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5405, 19135, 'Flibanserin', 'Grapefruit juice may increase the plasma concentrations of flibanserin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors such as grapefruit juice is considered contraindicated.  The patient should be advised to avoid the consumption of grapefruit and grapefruit juice during treatment, and to take flibanserin at bedtime to minimize the risk of hypotension, syncope, accidental injury, and central nervous system depression.  In addition, patients should consume no more than 1 to 2 alcoholic drinks and discontinue drinking alcohol at least two hours before taking flibanserin at bedtime; otherwise, they should skip the flibanserin dose that evening.  Alcohol should not be consumed until at least the morning after taking flibanserin at bedtime.  A standard alcoholic drink contains 14 g of pure alcohol and is equivalent to one 12-ounce regular beer (5% alcohol), 5-ounces wine (12% alcohol), or 1.5 ounces of distilled spirits/shot (40% alcohol).', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5406, 31966, 'Flibanserin', 'Grapefruit juice may increase the plasma concentrations of flibanserin.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.', 'grapefruit juice', 'Major', 'Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors such as grapefruit juice is considered contraindicated.  The patient should be advised to avoid the consumption of grapefruit and grapefruit juice during treatment, and to take flibanserin at bedtime to minimize the risk of hypotension, syncope, accidental injury, and central nervous system depression.  In addition, patients should consume no more than 1 to 2 alcoholic drinks and discontinue drinking alcohol at least two hours before taking flibanserin at bedtime; otherwise, they should skip the flibanserin dose that evening.  Alcohol should not be consumed until at least the morning after taking flibanserin at bedtime.  A standard alcoholic drink contains 14 g of pure alcohol and is equivalent to one 12-ounce regular beer (5% alcohol), 5-ounces wine (12% alcohol), or 1.5 ounces of distilled spirits/shot (40% alcohol).', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5407, 3433, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5408, 4861, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5409, 5026, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5410, 5029, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5411, 5039, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5412, 9138, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5413, 13870, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5414, 17273, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5415, 17971, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5416, 18156, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5417, 19154, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5418, 19235, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5419, 19237, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5420, 24087, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5421, 24885, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5422, 24886, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5423, 24887, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5424, 25454, 'Fluoxetine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5425, 2064, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5426, 3045, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5427, 6837, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5428, 6859, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5429, 13688, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5430, 13952, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5431, 13953, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5432, 15841, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5433, 15849, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5434, 18801, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5435, 18802, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5436, 26268, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5437, 26269, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5438, 26673, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5439, 27677, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5440, 29137, 'Amiodarone', 'Grapefruit juice may significantly increase the plasma concentrations of orally administered amiodarone.  The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.', 'grapefruit juice', 'Major', 'Patients treated with oral amiodarone should avoid consumption of grapefruits and grapefruit juice.  In addition, oral amiodarone should be administered consistently with regard to meals.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5441, 0, 'Flurazepam', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5442, 0, 'Fomepizole', 'The manufacturer reports that oral doses of fomepizole (10 to 20 mg/kg) will significantly reduce the rate of elimination of moderate doses of ethanol by approximately 40% when given to healthy volunteers.  The mechanism is via alcohol dehydrogenase inhibition.  By a similar mechanism, ethanol will decrease the rate of elimination of fomepizole.', 'alcohol', 'Major', 'In general, ethanol and fomepizole should not be coadministered in the treatment of ethylene glycol poisoning.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5443, 8269, 'Fluphenazine', 'Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during phenothiazine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5444, 8270, 'Fluphenazine', 'Concurrent use of ethanol and phenothiazines may result in additive CNS depression and psychomotor impairment.  Also, ethanol may precipitate dystonic reactions in patients who are taking phenothiazines.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during phenothiazine therapy.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5445, 19247, 'Fluvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5446, 21718, 'Fluvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5447, 26621, 'Fluvastatin', 'Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury.  Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins.  Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury.', 'alcohol', 'Moderate', 'Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5448, 5060, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5449, 5061, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5450, 5062, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5451, 5063, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5452, 5065, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5453, 5069, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5454, 5070, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5455, 13329, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5456, 17170, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5457, 19267, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5458, 19269, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5459, 19270, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5460, 19271, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5461, 31845, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5462, 32054, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5463, 33581, 'Folic acid', 'Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics.  Excessive alcohol consumption may lead to folate deficiency.', 'alcohol', 'Moderate', 'Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5464, 18357, 'Flurbiprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5465, 19418, 'Flurbiprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5466, 19420, 'Flurbiprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5467, 19421, 'Flurbiprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5468, 26942, 'Flurbiprofen', 'The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss.  The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.', 'alcohol', 'Moderate', 'Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5469, 4738, 'Fluvoxamine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5470, 4739, 'Fluvoxamine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5471, 5771, 'Fluvoxamine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5472, 10870, 'Fluvoxamine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5473, 19256, 'Fluvoxamine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5474, 19257, 'Fluvoxamine', 'Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.  Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.', 'alcohol', 'Moderate', 'Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5475, 0, 'Fosamprenavir', 'Food may reduce the systemic bioavailability of amprenavir from fosamprenavir oral suspension.  The mechanism of interaction has not been described.  According to the product labeling, administration of fosamprenavir oral suspension (1400 mg single dose) with a high-fat meal (967 kcal, 67 g fat, 33 g protein, 58 g carbohydrate) reduced amprenavir peak plasma concentration (Cmax) by 46% and systemic exposure (AUC) by 28% compared to administration in a fasted state.', 'high-fat foods', 'Moderate', 'Fosamprenavir suspension should be administered on an empty stomach in adults, but with food in pediatric patients to aid palatability and compliance.  If emesis occurs within 30 minutes after dosing the suspension, the dose should be repeated.  Fosamprenavir tablets may be taken with or without food.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5476, 11749, 'Amitriptyline', 'Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5477, 11750, 'Amitriptyline', 'Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5478, 13954, 'Amitriptyline', 'Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5479, 13955, 'Amitriptyline', 'Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5480, 20050, 'Amitriptyline', 'Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5481, 28599, 'Amitriptyline', 'Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5482, 29961, 'Amitriptyline', 'Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5483, 31522, 'Amitriptyline', 'Concomitant use of ethanol and a tricyclic antidepressant (TCA) may result altered TCA plasma levels and efficacy, and additive impairment of motor skills, especially driving skills.  Acute ethanol ingestion may inhibit TCA metabolism, while chronic ingestion of large amounts of ethanol may induce hepatic TCA metabolism.', 'alcohol', 'Moderate', 'Patients should be advised to avoid alcohol during TCA therapy.  Alcoholics who have undergone detoxification should be monitored for decreased TCA efficacy.  Dosage adjustments may be required.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5484, 2177, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5485, 5954, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5486, 18352, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5487, 18425, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5488, 20272, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5489, 20929, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5490, 20930, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5491, 20931, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5492, 24859, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5493, 24872, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5494, 24875, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5495, 24876, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5496, 24877, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5497, 24878, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5498, 24879, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5499, 24880, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
INSERT OR IGNORE INTO food_interactions (id, med_id, trade_name, interaction, ingredient, severity, management_text, mechanism_text, reference_text, source, created_at) VALUES (5500, 24881, 'Fosphenytoin', 'Acute consumption of alcohol may increase plasma phenytoin levels.  Chronic consumption of alcohol may decrease plasma phenytoin levels.  The mechanism of this interaction is related to induction of phenytoin metabolism by ethanol during chronic administration.  Other hydantoin derivatives may be similarly affected by ethanol.', 'alcohol', 'Moderate', 'Patients receiving phenytoin therapy should be warned about the interaction between phenytoin and ethanol and they should be advised to notify their physician if they experience worsening of seizure control or symptoms of toxicity, including drowsiness, visual disturbances, change in mental status, nausea, or ataxia.', NULL, NULL, 'DDInter', 0);
